The addition of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to ET in the treatment of advanced-stage breast cancer has boosted responses and survival outcomes over the past few years, especially in the first-line setting (8). This evidence concerns the gene CDK4 and breast carcinoma.